253
Participants
Start Date
March 31, 2016
Primary Completion Date
September 30, 2021
Study Completion Date
September 30, 2021
ANG-3777
Placebo
Mount Sinai School of Medicine, New York
Columbia University Medical Center, New York
Montefiore Medical Center BRANY, The Bronx
University of Pennsylvania, Philadelphia
Medstar Georgetown University Hospital, Washington D.C.
University of Maryland Medical Center, Baltimore
University of Virginia, Charlottesville
Virginia Commonwealth University (VCU) Medical Center of Virginia, Richmond
Wake Forest Baptist Health, Winston-Salem
Tampa General Hospital, Tampa
University of Louisville, Louisville
Ohio State University Medical Center, Columbus
University of Cincinnati, Cincinnati
University of Michigan Medical Center, Ann Arbor
Medical College of Wisconsin, Milwaukee
University of Minnesota Medical Center, Minneapolis
Northwestern University, Evanston
Rush University, Chicago
Barnes-Jewish Hospital, St Louis
Kansas University, Lawrence
Houston Methodist Hospital, Houston
University of Colorado Hospital Anschuts Medical Campus, Aurora
Mayo Clinic Hospital in Arizona, Phoenix
Keck Hospital of USC, Los Angeles
UCLA Medical Center, Los Angeles
California Institute of Renal Research, San Diego
California Pacific Medical Center (Sutter), San Francisco
University of California San Francisco Medical Center, San Francisco
UC Davis Medical Center, Sacramento
University of Washinton Medical Center, Seattle
Lead Sponsor
Collaborators (1)
CTI Clinical Trial and Consulting Services
OTHER
Angion Biomedica Corp
INDUSTRY